A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozadenant (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Acronyms TOZ-PD
Sponsors Acorda Therapeutics; Biotie Therapies Corp.

Most Recent Events

03 Apr 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
13 Dec 2018 This trial has been completed in Germany according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight